Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260

Regulatory Peptides

Volumn 141, Issue 1-3, 2007, Pages 12-18

  Molnár, Andor H ^a   Varga, Csaba ^a   Janáky, Tamás ^a   Tóth, Gábor ^a   Tóth, Géza ^b   Farkas, Judit ^b   László, Ferenc ^a   László, Ferenc A ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF BIOCHEMISTRY   (Hungary)

Author keywords

3H arginine vasopressin; Biological half life; Organ distribution; Vasopressin receptor antagonist

Indexed keywords

ARGIPRESSIN; MOZAVAPTAN;

ARTICLE; HALF LIFE TIME; KIDNEY; NEUROHYPOPHYSIS; ORGAN WEIGHT; PRIORITY JOURNAL; RADIOACTIVITY;

ANIMALS; ARGININE VASOPRESSIN; BENZAZEPINES; HALF-LIFE; KIDNEY; MALE; PITUITARY GLAND, ANTERIOR; PITUITARY GLAND, POSTERIOR; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; TISSUE DISTRIBUTION; TRITIUM;

RATTUS; RATTUS NORVEGICUS;

EID: 33947713987     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.12.011     Document Type: Article

References (51)

1. Laszlo F.A., Varga C., and Nakamura S. Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage. Eur J Pharmacol 364 (1999) 115-122
2. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 138 (2001) 18-21
3. Guyader D., Patat A., Ellis-Grosse E.J., and Orczyk G.P. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 36 (2002) 1197-1205
4. Wong F., Blei A.T., Blendis L.M., and Thuluvath P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37 (2003) 182-191
5. Claybaugh J.R., and Uyehara C.F. Metabolism of neurohypophysial hormones. Ann NY Acad Sci 689 (1993) 250-268
6. Nitschke U., and Balzar H. Inactivation of infused vasopressin in diabetes insipidus probands. Acta Endocrinol (Copenh) 62 (1969) 270-282
7. Weitzman R.E., and Fisher D.A. Arginine vasopressin metabolism in dogs. I. Evidence for a receptor-mediated mechanism. Am J Physiol 235 (1978) E591-E597
8. Wilson K.C., Weitzman R.E., and Fisher D.A. Arginine vasopressin metabolism in dogs. II. Modeling and system analysis. Am J Physiol 235 (1978) E598-E605
9. Yamamura Y., Ogawa H., Yamashita H., Chihara T., Miyamoto H., Nakamura S., Onogawa T., Yamashita T., Hosokawa T., Mori T., et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105 (1992) 787-791
10. Yamamura Y., Ogawa H., Kondo K., Yamashita H., Chihara T., Nakamura S., Onogawa T., Yamashita T., Yamada Y., Tsujimae K., Mori T., Tominaga M., and Yabuuchi Y. Development and pharmacology of non-peptide V1 and V2 vasopressin receptor antagonists. In: Gross P., Richter D., and Robertson G.L. (Eds). Vasopressin (1993), John Libbey Eurotext 507-515
11. Dogterom J., van Wimersma Greidanus T.B., and De Wied D. Vasopressin in cerebrospinal fluid and plasma of man, dog, and rat. Am J Physiol 234 (1978) E463-E467
12. Jojart I., Laczi F., Laszlo F.A., Boda K., Csati S., and Janaky T. Hyponatremia and increased secretion of vasopressin induced by vincristine administration in rat. Exp Clin Endocrinol 90 (1987) 213-220
13. Laczi F., Janaky T., Ivanyi T., Julesz J., and Laszlo F.A. Osmoregulation of arginine-8-vasopressin secretion in primary hypothyroidism and in Addison's disease. Acta Endocrinol (Copenh) 114 (1987) 389-395
14. Hunter W.M., and Greenwood F.C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194 (1962) 495-496
15. Laczi F., Fekete M., and de Wied D. Antidiuretic activity and immunoreactive arginin-vasopressin levels in eye plexus blood during passive avoidance behavior in rats. Life Sci 32 (1983) 577-589
16. De Wied D. A simple automatic and sensitive method for the assay of antidiuretic hormone with notes on the antidiuretic potency of plasma under different experimental conditions. Acta Physiol Pharmacol Neerl 9 (1960) 69-81
17. Laszlo F.A., Laszlo Jr. F., and De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 43 (1991) 73-108
18. Laszlo F.A., Varga C., Papp A., Pavo I., and Fahrenholz F. Difference between male and female rats in vasopressor response to arginine vasopressin. Acta Physiol Hung 81 (1993) 137-145
19. Pavo I., Laszlo F., Morschl E., Nemcsik J., Berko A., Cox D.A., and Laszlo F.A. Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats. Eur J Pharmacol 410 (2000) 101-104
20. Janaky T., Laszlo F.A., Sirokman F., and Morgat J.L. Biological half-life and organ distribution of [3H]8-arginine-vasopressin in the rat. J Endocrinol 93 (1982) 295-303
21. Laszlo F.A., Janaky T., Balaspiri L., and Morgat J.L. Biological half-life and organ distribution of [3H]1-deamino-8-d-arginine-vasopressin in the rat. J Endocrinol 88 (1981) 181-186
22. Grove L., Christensen P., and Bie P. Effects of receptor blockade on the natriuretic action of vasopressin. The First Joint World Congress of Neurohypophysis and Vasopressin (1995) 139
23. Burnier M., Fricker A.F., Hayoz D., Nussberger J., and Brunner H.R. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 55 (1999) 633-637
24. Czaczkes J.W., and Kleeman C.R. The effect of various states of hydration and the plasma concentration on the turnover of antidiuretic hormone in mammals. J Clin Invest 43 (1964) 1649-1658
25. Czaczkes J.W., Kleeman C.R., and Koenig M. Physiologic studies of antidiuretic hormone by its direct measurement in human plasma. J Clin Invest 43 (1964) 1625-1640
26. Laszlo F.A., Nagy E., Gaspar L., Keri G., and Teplan I. Effect of thirsting on the biological half-life and organ-distribution of 3H-lysin vasopressin. Horm Metab Res 12 (1980) 471-475
27. Janaky T., Laszlo F.A., Balaspiri L., and Morgat J.L. Effects of thirsting on biological half-life and organ distribution of 3H-dDAVP in rat. Horm Metab Res 14 (1982) 385-386
28. Fabian M., Forsling M.L., Jones J.J., and Pryor J.S. The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. J Physiol 204 (1969) 653-668
29. Kimura T., and Share L. Characterization of the renal handling of vasopressin in the dog by stop-flow analysis. Endocrinology 109 (1981) 2089-2094
30. Rabkin R., Share L., Payne P.A., Young J., and Crofton J. The handling of immunoreactive vasopressin by the isolated perfused rat kidney. J Clin Invest 63 (1979) 6-13
31. Baumann G., and Dingman J.F. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 57 (1976) 1109-1116
32. Shade R.E., and Share L. Renal vasopressin clearance with reductions in renal blood flow in the dog. Am J Physiol 232 (1977) F341-F347
33. Nardacci N.J., Mukhopadhyay S., and Campbell B.J. Partial purification and characterization of the antidiuretic hormone-inactivating enzyme from renal plasma membranes. Biochim Biophys Acta 377 (1975) 146-157
34. Lutz W., Sanders M., Salisbury J., and Kumar R. Internalization of vasopressin analogs in kidney and smooth muscle cells: evidence for receptor-mediated endocytosis in cells with V2 or V1 receptors. Proc Natl Acad Sci U S A 87 (1990) 6507-6511
35. Argent N.B., Wilkinson R., and Baylis P.H. Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. Clin Sci (Lond) 83 (1992) 583-587
36. Keeler R., Sato A.K., Claybaugh J.R., and Wilson N. Effect of V2 antagonist on clearance of arginine vasopressin by isolated perfused rat kidneys. Am J Physiol 261 (1991) R665-R669
37. Lauson H.D., Bocanegra M., and Beuzeville C.F. Hepatic and renal clearance of vasopressin from plasma of dogs. Am J Physiol 209 (1965) 199-214
38. Little J.B., Klevay L.M., Radford Jr. E.P., and McGandy R.B. Antidiuretic hormone inactivation by isolated perfused rat liver. Am J Physiol 211 (1966) 786-792
39. Rabkin R., Ghazeleh S., Share L., Crofton J., and Unterhalter S.A. Removal of immunoreactive arginine vasopressin by the perfused rat liver. Endocrinology 106 (1980) 930-934
40. Wittkowski J.K. Pituicytes. In: Federoff D.S., and Vernadakis A. (Eds). Astrocytes vol. 1 (1986), Academic, New York 173-208
41. Bunn S.J., Hanley M.R., and Wilkin G.P. Autoradiographic localization of peripheral benzodiazepine, dihydroalprenolol and arginine vasopressin binding sites in the pituitaries of control, stalk transected and Brattleboro rats. Neuroendocrinology 44 (1986) 76-83
42. Dashwood M.R., and Robinson I.C. Specificity of vasopressin binding to the posterior pituitary gland in the rat. An autoradiographic study. Neuroendocrinology 48 (1988) 180-187
43. Willumsen N.B., and Bie P. Tissue to plasma ratios of radioactivity in the rat hypothalamo-hypophyseal system after intravenous injection of 3H-lysine-vasopressin and 3H-mannitol. Acta Endocrinol (Copenh) 60 (1969) 389-400
44. Kjaer A., Knigge U., Bach F.W., and Warberg J. Impaired histamine- and stress-induced secretion of ACTH and beta-endorphin in vasopressin-deficient Brattleboro rats. Neuroendocrinology 57 (1993) 1035-1041
45. Laszlo F.A., Varga C., Pavo I., Gardi J., Vecsernyes M., Galfi M., Morschl E., Laszlo F., and Makara G.B. Vasopressin pressor receptor-mediated activation of HPA axis by acute ethanol stress in rats. Am J Physiol Regul Integr Comp Physiol 280 (2001) R458-R465
46. Lightman S.L., and Young W.S. Corticotrophin-releasing factor, vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the rat. J Physiol 403 (1988) 511-523
47. McCann S.M. The ACTH-releasing activity of extracts of the posterior lobe of the pituitary in vivo. Endocrinology 60 (1957) 664-676
48. McCann S.M., Antunes-Rodrigues J., Nallar R., and Valtin H. Pituitary-adrenal function in the absence of vasopressin. Endocrinology 79 (1966) 1058-1064
49. Mormede P., LeMoal M., and Dantzer R. Analysis of the dual mechanism of ACTH release by arginine vasopressin and its analogs in conscious rats. Regul Pept 12 (1985) 175-184
50. Rivier C., and Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, cathecolamines and vasopressin. Nature 305 (1983) 325-327
51. Pliska V., Thorn N.A., and Vilhardt H. In vitro uptake and breakdown of tritiated lysine-vasopressin by bovine neurohypophyseal and cortical tissue. Acta Endocrinol (Copenh) 67 (1971) 12-22